J.D. Durkin joins us live from D.C. with the latest on the looming government shutdown, and President Trump's efforts to take credit for advances in the aviation industry. Taylor Swift is getting a bad reputation with her fans. The star is catching flack for markups and gimmicks used in marketing her upcoming world tour. Not a single of swift's 33 North American dates have sold out since going on sale on December 13th. Fans blame Ticketmaster's Verified Fans program for their frustration. The program required fans to pre-register, and gave ticket-buyers the chance to improve their spot in line by buying merchandise. Snapchat may soon follow YouTube's ad strategy after the company's ad sales team found that users often skip an ad within the first one second of its stream. The social media platform may start implementing a mandatory three-seconds of commercial space before users can 'skip' ahead of content.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More